RAPT Therapeutics (NASDAQ:RAPT – Get Rating) had its target price trimmed by Guggenheim from $55.00 to $48.00 in a research report released on Wednesday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.
A number of other equities analysts also recently issued reports on RAPT. HC Wainwright decreased their price target on shares of RAPT Therapeutics from $50.00 to $43.00 and set a buy rating for the company in a research note on Wednesday. The Goldman Sachs Group initiated coverage on shares of RAPT Therapeutics in a research note on Thursday, December 1st. They issued a buy rating and a $27.00 price target for the company. Cantor Fitzgerald decreased their price target on shares of RAPT Therapeutics from $44.00 to $40.00 in a research note on Wednesday. Piper Sandler cut their price objective on shares of RAPT Therapeutics from $34.00 to $33.00 in a report on Thursday, December 8th. Finally, Wells Fargo & Company cut their price objective on shares of RAPT Therapeutics from $55.00 to $48.00 and set an overweight rating on the stock in a report on Wednesday, January 4th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of Buy and a consensus price target of $41.38.
RAPT Therapeutics Price Performance
RAPT stock opened at $18.94 on Wednesday. RAPT Therapeutics has a 1 year low of $9.85 and a 1 year high of $32.45. The firm has a 50-day moving average of $27.10 and a 200 day moving average of $23.28.
Institutional Investors Weigh In On RAPT Therapeutics
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD boosted its holdings in RAPT Therapeutics by 9.1% in the second quarter. Price T Rowe Associates Inc. MD now owns 4,334,683 shares of the company’s stock worth $79,108,000 after purchasing an additional 359,978 shares during the last quarter. FMR LLC boosted its holdings in RAPT Therapeutics by 28.7% in the second quarter. FMR LLC now owns 4,096,166 shares of the company’s stock worth $74,756,000 after purchasing an additional 913,465 shares during the last quarter. Column Group LLC boosted its holdings in RAPT Therapeutics by 91.2% in the second quarter. Column Group LLC now owns 2,680,458 shares of the company’s stock worth $48,918,000 after purchasing an additional 1,278,450 shares during the last quarter. BlackRock Inc. boosted its holdings in RAPT Therapeutics by 0.3% in the third quarter. BlackRock Inc. now owns 2,062,659 shares of the company’s stock worth $49,627,000 after purchasing an additional 6,076 shares during the last quarter. Finally, State Street Corp boosted its holdings in RAPT Therapeutics by 8.3% in the first quarter. State Street Corp now owns 1,347,581 shares of the company’s stock worth $29,633,000 after purchasing an additional 103,794 shares during the last quarter.
RAPT Therapeutics Company Profile
Rapt Therapeutics, Inc operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.
- Get a free copy of the StockNews.com research report on RAPT Therapeutics (RAPT)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.